A matched pair analysis of intra- and postoperative catumaxomab in patients with ovarian cancer from a multicenter, single-arm phase II trial versusĀ a consecutive single-center collective of ovarian cancer patients without immunotherapy.
Klaus Pietzner
Honoraria - Fresenius Biotech
Radoslav Chekerov
No relevant relationships to disclose
Alexander Reinthaller
No relevant relationships to disclose
Daniel Reimer
No relevant relationships to disclose
Toralf Reimer
No relevant relationships to disclose
Lukas Angleitner-Boubenizek
No relevant relationships to disclose
Miriam Tschirschmann
Employment or Leadership Position - Fresenius Biotech
Horst Lindhofer
Employment or Leadership Position - TRION Research
Stock Ownership - TRION Research
Elena Ioana Braicu
No relevant relationships to disclose
Christina Fotopoulou
No relevant relationships to disclose
Jalid Sehouli
No relevant relationships to disclose